However, multiple ongoing studies aim to deepen our understanding of the COVID-19 receptor-RAS interaction, with examples including: “Angiotensin 1-7 as a Therapy for Pneumonia Caused by Coronavirus 2 (SARS-CoV-2)” (NCT04605887): A phase 2, double-blind, randomized study focuses on Ang 1-7 investigates subcutaneous Ang 1-7 therapy at 500 mcg/kg/day to address the potential role of ACE-2-Ang-(1-7)-MasR in mitigating SARS-CoV-2's effects. The gene discussed is ANGPT1; the disease is pneumonia.